Advancing access to therapeutic botulinum toxins through biosimilarity
Increasing access to therapeutic botulinum toxin treatments matters because these therapies are clinically proven to improve symptoms and function across a wide range of neuromuscular conditions – yet access remains constrained by cost, coverage limitations, and limited product competition. We are dedicated to expanding availability by developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX®, aiming to bring a high-quality, evidence-driven therapeutic option to patients, providers, and payers. Our bold approach has the potential to broaden treatment access for millions of people while delivering new value across the healthcare system.
Our approach
By leveraging the FDA’s biosimilar pathway, together with a globally validated botulinum toxin complex and an established, FDA-inspected manufacturing platform, we are uniquely positioned to bring a full-label therapeutic entrant into a category long constrained by cost, coverage, and limited competition. Focusing solely on therapeutic indications enables us to align more effectively with payers and healthcare systems, where biosimilars have consistently expanded access and created meaningful economic value, while supporting high-quality care across the therapeutic indications for which Botox® is currently approved.
Our pipeline
Our lead candidate, ABP-450 (prabotulinumtoxinA), is being developed as a branded biosimilar to BOTOX®, with the goal of expanding access to treatment across the therapeutic indications for which Botox® is approved. By combining a well-characterized toxin complex with a rigorous biosimilarity program, ABP-450 is designed to offer a high-quality, full-label therapeutic alternative that builds on extensive global experience with the molecule and aligns with the needs of patients, providers, and payers.
To learn more about our science, investment and business development opportunities, partnerships, or careers, send us a message.